

Because NHSN did not hold the live annual training in 2020, please plan to use the 2019 NHSN Annual Training videos and slides for NHSN training throughout 2020.

Although there were not extensive changes made to the NHSN PSC protocols for 2020, NHSN wanted to note any differences between the training content provided in 2019 and the current 2020 protocols. Therefore, this document will detail changes to information presented in the 2019 videos and slides so that they align with the 2020 NHSN Patient Safety Component Manual updates.

The following slides will provide the slide number and slide information from the 2019 NHSN Training presentation and then explain updates or clarifications for 2020 related to the content provided in that particular slide.

2019 Annual NHSN Training

MDROs

Analyzing LabID Event Data in NHSN



2019 Presentation, Slide 13

Definitions

- **MDR-Acinetobacter**: Any *Acinetobacter* species testing non-susceptible (resistant or intermediate) to at least one agent in at least 3 antimicrobial classes of the following 6 antimicrobial classes:

Antimicrobial Class	Agents
β -lactams and β -lactam/ β -lactamase inhibitor combinations	Piperacillin, Piperacillin/tazobactam
Sulbactam	Ampicillin/sulbactam
Cephalosporins	Cefepime, Ceftazidime
Carbapenems	Imipenem, Meropenem, Doripenem, Ertapenem
Aminoglycosides	Amikacin, Gentamicin, Tobramycin
Fluoroquinolones	Ciprofloxacin, Levofloxacin

- **CephR**- *Klebsiella oxytoca* or *Klebsiella pneumoniae* testing non-susceptible (either resistant or intermediate) to ceftazidime, cefotaxime, ceftriaxone, or cefepime.
- **CRE**- Any *Escherichia coli*, *Klebsiella oxytoca*, *Klebsiella pneumoniae*, *Klebsiella aerogenes* or *Enterobacter spp.* testing **resistant** to imipenem, meropenem, doripenem, or ertapenem by standard susceptibility testing methods (minimum inhibitory concentrations of ≥ 4 mcg/mL for doripenem, imipenem and meropenem or ≥ 2 mcg/mL for ertapenem) OR by production of a carbapenemase (specifically, KPC, NDM, VIM, IMP, OXA-48) demonstrated using a recognized test.

2019 Presentation, Slide 64

Incomplete Months

- SIR report will first display the SIR table
- Scroll down to view supplemental table

CDI Data - Incomplete Months Excluded for SIR

Date Range: All BS2_LABID_RATESCDIF

location	summaryYM	CDIF_labidCount	numPatDays	numAdms	cdiTestType	numbed	medAff
FACWIDEIN	2019M01	0	1450	976		50	N
FACWIDEIN	2019M02	1	1345	987		50	N



2020 Updates for Slide 64

Incomplete Months

- SIR report will first display the SIR table
- Scroll down to view supplemental table

CDI Data - Months Excluded from SIR Due to Missing CDI Test Type

Date Range: BS2_LABID_RATESCDIF summaryYr After and Including 2015

location	summaryYM	CDIF_facIncHOCCount	numPatDays	numAdms	cdiTestType
FACWIDEIN	2019M01	0	1450	976	
FACWIDEIN	2019M02	1	1345	987	

1. This table displays months that are excluded from the SIR report. These months will be included in the SIR once reporting for the entire quarter has been completed and CDI test type has been reported.